Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?
about
Natalizumab for relapsing remitting multiple sclerosisTreatment-related progressive multifocal leukoencephalopathy: current understanding and future stepsProgressive multifocal leukoencephalopathy: clinical and molecular aspectsInsights into the initiation of JC virus DNA replication derived from the crystal structure of the T-antigen origin binding domainLong-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosisInhibition of α4β1 integrin increases ovarian cancer response to carboplatin.Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System.Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathyLights and shadows of cyclophosphamide in the treatment of multiple sclerosisCritical appraisal of the role of fingolimod in the treatment of multiple sclerosis.Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis.From injection therapies to natalizumab: views on the treatment of multiple sclerosis.Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosisThe mesenchymal tumor microenvironment: a drug-resistant niche.Cognitive dysfunction with aging and the role of inflammationA review on JC virus infection in kidney transplant recipients.A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitisChanges to anti-JCV antibody levels in a Swedish national MS cohortInterdisciplinary Risk Management in the Treatment of Multiple Sclerosis.Principles of a new treatment algorithm in multiple sclerosis.Progressive multifocal leukoencephalopathy and natalizumab.What happens when natalizumab therapy is stopped?Treating multiple sclerosis with natalizumab.Integrins as receptor targets for neurological disordersEvolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing.Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards.Multiple sclerosis treatment and infectious issues: update 2013.The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.αvβ3- or α5β1-Integrin-Selective Peptidomimetics for Surface Coating.Multiple sclerosis: an example of pathogenic viral interaction?Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.Early magnetic resonance detection of natalizumab-related progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.[Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs].Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society. December 5-9, 2010, San Diego, CA USA.The cohort of the multiple sclerosis center of Cagliari.
P2860
Q24235861-B8B937C1-6BBA-48E0-9630-06A1BC72EBD0Q26823444-A092F831-65A5-4E23-B405-421707061453Q26858968-B9B8D20D-6EEE-49CC-A5BE-73BBF49F9C85Q27681947-3D2686D4-7187-41C8-951D-755B88CC9458Q28730755-530BBF83-7988-4841-9B60-4EA3792B35ABQ30408322-80D1A0C2-B4B2-4C79-9861-F0202DD3D900Q33770508-214D615F-BE6D-4247-92D9-6AD2617AB86AQ34324861-CA0149B9-1177-4271-A93B-A7D186F1BF58Q34922742-972F809F-2023-43B6-A4F9-A7DB87008A95Q35212994-22641351-C806-455A-9743-E5BF7B083DCFQ35606563-49757672-6D41-44D7-A06D-3D2549A142D9Q35825914-E8E2528D-8D01-446F-8DC5-137E0814EA85Q36145715-C65A6A75-DA1C-40D3-BE9B-8E25B4E29CC9Q36187755-AD761424-78DA-4E0F-864B-BC1B8C59C1EAQ36443732-AB75F48A-15C3-45AB-B946-97B67297160BQ36602840-DDAD2896-188F-49E1-856A-0E34CBE1D9F8Q37012710-34DCA4F5-A446-4F47-B586-4F32ECC04D1EQ37267644-75819564-7260-4AE1-8FD7-F7AC106F1AA3Q37615119-60C810E9-BE73-4B63-835D-AB379B8C0818Q37849763-C3F5DB5A-E1B5-488C-A60C-B63A25A31210Q37885823-B2AE16AB-6450-4AC6-98BF-00D11CE8AE97Q37921761-B4601AF4-0E04-4364-9F8D-51F81F09BEE8Q37957123-0088983C-528D-4202-879A-2B3872A67814Q37974737-D6D84C67-7706-4CB7-B3BF-39B822C70DCEQ38029235-07D90D03-AA95-4515-BDA7-ADD92D453A8BQ38068499-265AFA60-0594-430F-9D92-3741020596A3Q38116451-3231A084-F259-4FB5-9261-F170413C2A82Q38153471-4EEBC100-5857-4405-825C-17D40092537EQ38186206-FB8D9EE9-86C7-48EE-B645-5D799A6F24EAQ38268951-3FB78C34-E59C-4D70-8994-2B7AB48C09A0Q38591114-7D8BA993-1647-4059-9EA5-6F02335E1E67Q38815391-E2B2585C-0DEA-4A82-A3F4-5FF2BC153DB5Q38852942-2F3FFE09-009A-46DC-964C-6A917A3BAFDCQ39152931-3EBF91AE-8602-49F7-A0BC-C60297A86EFEQ39211049-CFB621E2-8EF0-4C9F-9526-9F32F36C9DCCQ39303279-DB5DD900-E440-4768-9459-B96603872790Q41102105-FAB55DAF-62FF-4D6F-86C3-FE6D17E906FBQ42181572-902BB6FD-B459-4D71-964E-C3834234FF82Q42732010-21F8E992-DBDF-4494-A7ED-7B144DAD1255Q44178125-0859FEAB-9D67-48C0-A1D5-E1BB7A5A289A
P2860
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Natalizumab and progressive mu ...... factors and can it be avoided?
@en
Natalizumab and progressive mu ...... factors and can it be avoided?
@nl
type
label
Natalizumab and progressive mu ...... factors and can it be avoided?
@en
Natalizumab and progressive mu ...... factors and can it be avoided?
@nl
prefLabel
Natalizumab and progressive mu ...... factors and can it be avoided?
@en
Natalizumab and progressive mu ...... factors and can it be avoided?
@nl
P2093
P2860
P50
P1433
P1476
Natalizumab and progressive mu ...... factors and can it be avoided?
@en
P2093
Benjamin M Greenberg
Bernhard Hemmer
Clemens Warnke
Elliot M Frohman
Jeffrey L Bennett
Michael K Racke
Petra D Cravens
Scott S Zamvil
P2860
P304
P356
10.1001/ARCHNEUROL.2010.161
P577
2010-08-01T00:00:00Z